Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 avr. 2026 12h13 HE | Source: Bragar Eagel & Squire

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options If you purchased or...
17 avr. 2026 11h10 HE | Source: Schall Law

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
16 avr. 2026 23h57 HE | Source: The Rosen Law Firm PA

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026...
16 avr. 2026 13h02 HE | Source: Hagens Berman Sobol Shapiro LLP

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
16 avr. 2026 10h40 HE | Source: SkyMedia, LLC

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW ORLEANS, April 16, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a...
16 avr. 2026 09h00 HE | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

LOS ANGELES, April 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors...
16 avr. 2026 08h38 HE | Source: Bernstein Liebhard LLP

IBRX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc.

ImmunityBio Shareholders Between January 19, 2026 and March 24, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
14 avr. 2026 22h11 HE | Source: Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026Basis:...
14 avr. 2026 16h35 HE | Source: Hagens Berman Sobol Shapiro LLP

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
14 avr. 2026 10h20 HE | Source: Schall Law

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Page suivante